Insider Trading March 16, 2026

Enovis CAO Buys 1,000 Shares as Company Posts Mixed Q4 Results

Oliver Engert increases direct stake while Enovis reports beat on EPS but a revenue shortfall and issues cautious 2026 revenue guidance

By Caleb Monroe ENOV
Enovis CAO Buys 1,000 Shares as Company Posts Mixed Q4 Results
ENOV

Enovis Corporation Chief Administrative Officer Oliver Engert purchased 1,000 shares on March 13, 2026, at $23.74 per share, bringing his direct holdings to 48,640 shares. The transaction occurred while the stock trades well below its 52-week high. The company reported fourth-quarter 2025 results showing EPS above expectations but revenue slightly below forecasts, and issued 2026 guidance that is mixed versus consensus.

Key Points

  • Insider transaction: CAO Oliver Engert purchased 1,000 shares on March 13, 2026, at $23.74, now directly owning 48,640 shares - impacts investor sentiment and insider confidence.
  • Quarterly results were mixed: Q4 2025 EPS of $0.95 beat the $0.82 estimate, while revenue of $575.7 million missed the $584.71 million consensus - relevant to company valuation and revenue-driven valuation models.
  • 2026 guidance is mixed: revenue expected below consensus, EBITDA in line with consensus, and EPS above consensus; Needham raised its price target to $52 from $49 and maintained a Buy rating - important for equity analysts and healthcare investors.

Enovis Corporation reported an insider purchase this week as Chief Administrative Officer Oliver Engert picked up 1,000 shares of company stock on March 13, 2026, at a purchase price of $23.74 per share. The transaction was valued at $23,740 and raises Engert's direct ownership to 48,640 shares.

The insider buy occurred while Enovis shares trade near $23.21, a level considerably lower than the company's 52-week peak of $40.70. The share price has declined roughly 41% over the past year, underscoring the gap between current market value and last year's high-water mark.

Market commentary included an InvestingPro assessment that ENOV currently appears undervalued, with a Fair Value estimate that suggests upside potential at present trading levels. Investors interested in deeper analysis can consult the Pro Research Report available for ENOV and more than 1,400 other U.S. equities.

Separately, Enovis released its fourth-quarter 2025 financial results. Earnings per share for the quarter came in at $0.95, ahead of the consensus estimate of $0.82. Revenue for the same period totaled $575.7 million, which was slightly below the expected $584.71 million.

Management provided guidance for 2026 that contains a mix of signals relative to market expectations: revenue guidance is set below consensus, EBITDA is expected to be in line with consensus, and EPS guidance is projected to come in above consensus estimates.

Following the quarterly report, Needham adjusted its price target for Enovis upward to $52 from $49 while maintaining a Buy rating on the stock. Analysts and investors have pointed to the company’s profitability metrics and recent product initiatives as drivers behind the favorable reception to the earnings print.

Overall, the insider purchase by Engert and the company’s mixed quarterly performance have drawn attention. The transaction represents a direct, albeit modest, increase in an executive's stake, while the financial results and guidance present a mixed picture for investors weighing valuation, near-term revenue trajectory, and profitability outlook.


Summary: Oliver Engert bought 1,000 Enovis shares at $23.74 on March 13, 2026, bringing his direct holdings to 48,640 shares. The company reported Q4 2025 EPS of $0.95 versus a $0.82 forecast and revenue of $575.7 million versus an expected $584.71 million. Guidance for 2026 expects revenue below consensus, EBITDA in line, and EPS above consensus. Needham raised its price target to $52 and kept a Buy rating.

Risks

  • Stock price has declined about 41% from its 52-week high of $40.70, reflecting downside risk for equity investors and potential market skepticism.
  • Enovis’s Q4 revenue missed expectations, a factor that could weigh on near-term top-line performance and investor confidence in the medical devices sector.
  • Management’s 2026 revenue guidance is below consensus, introducing uncertainty about growth prospects and potential pressure on the company’s valuation.

More from Insider Trading

Casella Waste Director Sells Shares to Cover RSU Taxes; Retains Substantial Class B Stake Mar 16, 2026 Casella Waste CEO Sells $120,610 in Stock as Company Posts Mixed Quarter Mar 16, 2026 Viasat Commercial Head Executes $110,904 Share Sale Amid Elevated Stock Levels Mar 16, 2026 Circle Internet Director Executes Pre-Planned Sale, Retains Substantial Stake as USDC Momentum Continues Mar 16, 2026 Pagaya Technologies President Sells $106,624 in Stock to Cover Tax Obligations Mar 16, 2026